Human in vitro glutathionyl and protein adducts of carbamazepine-10,11- epoxide, a stable and pharmacologically active metabolite of carbamazepine

Drug Metabolism and Disposition

Volumn 33, Issue 12, 2005, Pages 1920-1924

  Bu, Hai Zhi ^a   Kang, Ping ^a   Deese, Alan J ^a   Zhao, Ping ^a   Pool, William F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXY 11 GLUTATHIONYLCARBAMAZEPINE; 10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CARBON 14; DRUG METABOLITE; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; COVALENT BOND; DIASTEREOISOMER; EPOXIDATION; HUMAN; HUMAN CELL; LIVER MICROSOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; STATISTICAL SIGNIFICANCE;

CARBAMAZEPINE; GLUTATHIONE; HUMANS; MICROSOMES, LIVER; PROTEIN BINDING;

EID: 28144464500     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006866     Document Type: Article

References (15)

1. Amore BM, Kalhorn TF, Skiles GL, Hunter AP, Bennett GD, Finnell RH, Nelson SD, and Slattery JT (1997) Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicity. Drug Metab Dispos 25:953-962.
2. Askmark H and Wiholm B (1990) Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 81:131-140.
3. Bertilsson L and Tomson T (1986) Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 11:177-198.
4. Durelli L, Massazza U, and Cavallo R (1989) Carbamazepine toxicity and poisoning: incidence, clinical features and management. Med Toxicol Adverse Drug Exp 4:95-107.
5. Hart RG and Easton JD (1982) Carbamazepine and hematological monitoring. Ann Neurol 11:309-312.
6. Kalapos MP (2002) Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events - retrospective review of old data and call for new investigation. Adv Drug React Toxicol Rev 21:123-141.
7. Koppele JM and Mulder GJ (1991) Stereoselective glutathione conjugation by subcellular fractions and purified glutathione S-transferases. Drug Metab Rev 23:331-354.
8. Lillibridge JH, Amore BM, Slattery JT, Kalhorn TF, Nelson SD, Finnell RH, and Bennett GD (1996) Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos 24:509-514.
9. Liu H and Delgado MR (1994) The influence of polytherapy on the relationships between serum carbamazepine and its metabolites in epileptic children. Epilepsy Res 17:257-269.
10. Liu M, Mao X, Ye C, Huang H, Nicholson JK, and Lindon JC (1998) Improved WATERGATE pulse sequences for solvent suppression in NMR spectroscopy. J Magn Reson 132:125-129.
11. Madden S, Maggs JL, and Park BK (1996) Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 24:469-479.
12. Masubuchi Y, Nakano T, Ose A, and Horie T (2001) Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch Toxicol 75:538-543.
13. Pellock JM (1987) Carbamazepine side effects in children and adults. Epilepsia 28:S64-S70.
14. Pirmohamed M, Kitteringham NR, Guenthner TM, Breckenridge AM, and Park BK (1992) An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 43:1675-1682.
15. Shear NH, Spielberg SP, Cannon M, and Miller M (1988) Anticonvulsant hypersensitivity syndrome. In vitro risk assessment. J Clin Investig 82:1826-1832.